Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
SNY's reasonable valuation, rising estimates, improving top line and positive pipeline progress are good enough reasons to ...
FiercePharma2d
With amped up manufacturing effort, Sanofi and AZ look to avoid Beyfortus shortfalls this year
As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...
legit13h
After GSK, Sanofi Exit, Another Multinational Company Set to Leave Nigeria, Gives Reasons
PZ Cussons has decided to leave Nigeria, citing naira's devaluation as the reason after GSK, Sanofi and other multinationals ...
CD&R in Talks With Banks Over Debt to Fund Equity for Sanofi Arm
Clayton Dubilier & Rice is discussing the possibility of using borrowed money to fund a part of the equity check in its bid ...
FierceBiotech7d
Sanofi's $80M bet on Fulcrum's dystrophy drug ends in phase 3 failure after 4 months
Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a ...
FiercePharma8d
Sanofi, Regeneron to seek approval for Dupixent in bullous pemphigoid after positive phase 3 study
Sanofi and Regeneron’s superstar anti-inflammatory biologic Dupixent is on a roll. | It was a busy day for Sanofi and ...
devdiscourse2d
Panacea Biotec and Sanofi Settle Patent Dispute Over Hexavalent Vaccine
Panacea Biotec has reached a settlement with Sanofi Healthcare India concerning a patent infringement for its fully liquid ...
BioSpace7d
Sanofi Dips Into Red-Hot Radiopharma Space With $110M Licensing Deal
Sanofi will join Big Pharma peers Novartis, BMS and Eli Lilly in radioligands, striking a $110 million licensing deal with ...
Sanofi Teams Up With RadioMedix, Orano in $352 Mln Deal for Cancer Therapy -- Update
Sanofi agreed to pay up to 320 million euros ($352.4 million) to U.S. company RadioMedix and the biotechnology subsidiary of nuclear-fuel supplier Orano to license a potential treatment for rare ...
Yahoo Finance3d
SANOFI CONS HEALTHC IND L (SANOFICONR.NS)
Advisors Capital Management partner and portfolio manager JoAnne Feeney joins Morning Brief to discuss the political outlook for small caps (^RUT) and some of her top tech plays as the market ...